Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

The small molecule anticancer agent cisplatin and its Pt (II) analogs carboplatin and
oxaliplatin are widely used to treat a variety of tumorigenic diseases. Despite their structural …

This review provides an introduction into the fascinating area of organometallic anticancer
compounds. Although the subject dates back many years, it has witnessed considerable …

Bioorganometallic chemistry is a rapidly developing area of research. In recent years
organometallic compounds have provided a rich platform for the design of effective catalysts …

Interest in the medicinal properties of ruthenium (II)–arene compounds has grown rapidly
over the last decade. In this account we describe the origins of the field and subsequently …

8-Hydroxyquinoline and its derivatives have a broad variety of pharmacological properties,
which make them an ideal bioactive building block in the development of metal-based …

The rapid emergence of antimicrobial resistance (AMR) among bacterial pathogens results
in antimicrobial treatment failure and the high mortality rate associated with AMR. The …

A series of novel C, N-cyclometalated benzimidazole ruthenium (II) and iridium (III)
complexes of the types [(η6-p-cymene) RuCl (κ2-N, CL)] and [(η5-C5Me5) IrCl (κ2-N …

This review highlights the progress in the development of ruthenium (II)/(III) complexes with
flavone derivatives as potential therapeutic agents. We focused on natural hydroxyflavone …

Organometallic complexes offer potential for design as anticancer drugs. They can act as
inert scaffolds and specifically inhibit enzymes such as kinases, or as pro-drugs which …